차세대 항체 치료제 시장 분석 및 예측(-2035년) : 유형별, 제품 유형별, 기술별, 용도별, 프로세스별, 최종 사용자별, 개발 단계별, 배포별, 기능별, 모드별

Next Generation Antibody Therapeutics Market is anticipated to expand from $3.6 billion in 2024 to $9.4 billion by 2034, growing at a CAGR of approximately 10.1%. The Next Generation Antibody Therapeutics Market encompasses advanced biologic drugs engineered to enhance specificity, efficacy, and safety in treating diseases. This includes bispecific antibodies, antibody-drug conjugates, and engineered antibody fragments. Driven by innovations in molecular engineering and a focus on precision medicine, this market promises significant advancements in oncology, immunology, and infectious diseases, addressing unmet medical needs and expanding therapeutic applications.

The Next Generation Antibody Therapeutics Market is experiencing robust growth, propelled by advancements in biotechnology and precision medicine. Monoclonal antibodies lead the market, driven by their efficacy in targeted therapies for various diseases. Bispecific antibodies, offering dual-targeting capabilities, are the second-highest performing sub-segment, gaining traction for their potential in oncology treatments. Antibody-drug conjugates are also emerging as a critical segment, combining antibody specificity with potent cytotoxic agents. The oncology therapeutic area remains the top-performing segment, reflecting the high demand for innovative cancer treatments. Autoimmune diseases follow, benefiting from the development of novel antibody therapies aimed at modulating immune responses. Technological advancements, such as improved antibody engineering and production techniques, are accelerating market growth. The increasing focus on personalized medicine is driving demand for tailored antibody therapies. Strategic collaborations and partnerships among pharmaceutical companies are fostering innovation and expanding the therapeutic pipeline. Regulatory support and expedited approval processes further enhance market dynamics, facilitating the introduction of novel antibody therapeutics.

Market Snapshot:

Next Generation Antibody Therapeutics Market is witnessing a dynamic shift, with market share being dominated by innovative companies launching advanced therapeutics. Pricing strategies remain competitive, reflecting the high demand for more effective and targeted treatments. The market is characterized by a surge in new product launches, as companies strive to address unmet medical needs and enhance therapeutic efficacy. This competitive landscape is further invigorated by strategic collaborations and partnerships that aim to accelerate product development and market entry. In terms of competition benchmarking, key players are continuously innovating to maintain their competitive edge. Regulatory influences play a significant role, with stringent guidelines in North America and Europe impacting market dynamics. The regulatory landscape is evolving, encouraging transparency and safety in therapeutic development. Companies are investing heavily in research and development to navigate these regulations effectively. As the market continues to mature, advancements in antibody engineering and novel delivery platforms are expected to drive substantial growth, offering lucrative opportunities for stakeholders.

Geographical Overview:

The Next Generation Antibody Therapeutics Market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the market, propelled by substantial investments in biotechnology and a strong focus on innovative therapeutic solutions. The presence of major pharmaceutical companies and research institutions further bolsters the region's market dominance. Europe follows closely, with significant government support for biotechnological research and a well-established healthcare infrastructure. The region's emphasis on personalized medicine and advanced therapeutics enhances its market potential. In Asia Pacific, the market is expanding rapidly, driven by increasing healthcare expenditure and a growing focus on precision medicine. Countries like China and India are emerging as key players, with rising investments in biopharmaceutical research and development. Latin America and the Middle East & Africa are burgeoning markets with increasing potential. Brazil and Saudi Arabia are witnessing a surge in biotechnology investments, recognizing the importance of next-generation antibody therapeutics in advancing healthcare outcomes.

Key Trends and Drivers:

The Next Generation Antibody Therapeutics Market is experiencing robust growth driven by breakthroughs in biotechnology and personalized medicine. Key trends include the development of bispecific antibodies, which enhance targeting capabilities and therapeutic efficacy. The rise of antibody-drug conjugates (ADCs) is revolutionizing cancer treatment by delivering cytotoxic agents directly to cancer cells, minimizing collateral damage. The market is also witnessing an increased focus on monoclonal antibodies for autoimmune diseases, reflecting the demand for targeted therapies. Drivers include technological advancements in antibody engineering and a growing prevalence of chronic diseases. Regulatory approvals are accelerating, providing a favorable landscape for market expansion. Moreover, collaborations between biotech firms and research institutions are fostering innovation and expediting the development pipeline. Opportunities abound in emerging markets, where healthcare infrastructure is improving, and demand for advanced therapeutics is rising. Companies investing in robust R&D and strategic partnerships are well-positioned to capitalize on these burgeoning opportunities.

Restraints and Challenges:

The Next Generation Antibody Therapeutics Market is confronted with several significant restraints and challenges. One primary restraint is the high cost of development and production, which can be prohibitive for smaller companies and limit market entry. This financial barrier often results in a concentration of market power among a few large players, stifling innovation. Regulatory hurdles present another formidable challenge. The stringent approval processes for new therapeutics can delay market entry and increase costs. This regulatory environment demands extensive clinical trials, which are both time-consuming and expensive. The complexity of antibody production also poses a challenge. Manufacturing these therapeutics requires advanced technology and expertise, which can be difficult to scale efficiently. This complexity can lead to variability in product quality and supply chain issues. Market penetration is further hindered by competition from traditional therapies. Many healthcare providers and patients remain loyal to established treatments, slowing the adoption of new antibody therapeutics. Lastly, intellectual property and patent disputes can impede market growth. The competitive landscape is fraught with legal battles over proprietary technologies, diverting resources from research and development.

Key Players:

MacroGenics, ImmunoGen, MorphoSys, Genmab, Pieris Pharmaceuticals, AbCellera, Xencor, Adimab, MabSpace Biosciences, Harbour BioMed, Zymeworks, Bicycle Therapeutics, Crescendo Biologics, Mabion, I-Mab

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by Process
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Stage
• 2.8 Key Market Highlights by Deployment
• 2.9 Key Market Highlights by Functionality
• 2.10 Key Market Highlights by Mode

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Monoclonal Antibodies
  • 4.1.2 Bispecific Antibodies
  • 4.1.3 Antibody-Drug Conjugates
  • 4.1.4 Antibody Fragments
  • 4.1.5 Polyclonal Antibodies
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Therapeutic Antibodies
  • 4.2.2 Diagnostic Antibodies
  • 4.2.3 Research Antibodies
  • 4.2.4 Antibody Fragments
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Phage Display
  • 4.3.2 Hybridoma
  • 4.3.3 Transgenic Mouse
  • 4.3.4 Bacterial Display
  • 4.3.5 Yeast Display
  • 4.3.6 Mammalian Cell Display
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Oncology
  • 4.4.2 Autoimmune Diseases
  • 4.4.3 Infectious Diseases
  • 4.4.4 Cardiovascular Diseases
  • 4.4.5 Neurological Diseases
  • 4.4.6 Metabolic Diseases
• 4.5 Market Size & Forecast by Process (2020-2035)
  • 4.5.1 Discovery
  • 4.5.2 Development
  • 4.5.3 Manufacturing
  • 4.5.4 Quality Control
  • 4.5.5 Regulatory Approval
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Pharmaceutical Companies
  • 4.6.2 Biotechnology Companies
  • 4.6.3 Research Institutes
  • 4.6.4 Contract Research Organizations
• 4.7 Market Size & Forecast by Stage (2020-2035)
  • 4.7.1 Preclinical
  • 4.7.2 Clinical Trials
  • 4.7.3 Commercialized
• 4.8 Market Size & Forecast by Deployment (2020-2035)
  • 4.8.1 In-House
  • 4.8.2 Outsourced
• 4.9 Market Size & Forecast by Functionality (2020-2035)
  • 4.9.1 Targeted Therapy
  • 4.9.2 Immunotherapy
  • 4.9.3 Conjugation
• 4.10 Market Size & Forecast by Mode (2020-2035)
  • 4.10.1 Intravenous
  • 4.10.2 Subcutaneous
  • 4.10.3 Intramuscular
  • 4.10.4 Oral

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 Process
    • 5.2.1.6 End User
    • 5.2.1.7 Stage
    • 5.2.1.8 Deployment
    • 5.2.1.9 Functionality
    • 5.2.1.10 Mode
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 Process
    • 5.2.2.6 End User
    • 5.2.2.7 Stage
    • 5.2.2.8 Deployment
    • 5.2.2.9 Functionality
    • 5.2.2.10 Mode
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 Process
    • 5.2.3.6 End User
    • 5.2.3.7 Stage
    • 5.2.3.8 Deployment
    • 5.2.3.9 Functionality
    • 5.2.3.10 Mode
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 Process
    • 5.3.1.6 End User
    • 5.3.1.7 Stage
    • 5.3.1.8 Deployment
    • 5.3.1.9 Functionality
    • 5.3.1.10 Mode
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 Process
    • 5.3.2.6 End User
    • 5.3.2.7 Stage
    • 5.3.2.8 Deployment
    • 5.3.2.9 Functionality
    • 5.3.2.10 Mode
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 Process
    • 5.3.3.6 End User
    • 5.3.3.7 Stage
    • 5.3.3.8 Deployment
    • 5.3.3.9 Functionality
    • 5.3.3.10 Mode
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 Process
    • 5.4.1.6 End User
    • 5.4.1.7 Stage
    • 5.4.1.8 Deployment
    • 5.4.1.9 Functionality
    • 5.4.1.10 Mode
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 Process
    • 5.4.2.6 End User
    • 5.4.2.7 Stage
    • 5.4.2.8 Deployment
    • 5.4.2.9 Functionality
    • 5.4.2.10 Mode
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 Process
    • 5.4.3.6 End User
    • 5.4.3.7 Stage
    • 5.4.3.8 Deployment
    • 5.4.3.9 Functionality
    • 5.4.3.10 Mode
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 Process
    • 5.4.4.6 End User
    • 5.4.4.7 Stage
    • 5.4.4.8 Deployment
    • 5.4.4.9 Functionality
    • 5.4.4.10 Mode
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 Process
    • 5.4.5.6 End User
    • 5.4.5.7 Stage
    • 5.4.5.8 Deployment
    • 5.4.5.9 Functionality
    • 5.4.5.10 Mode
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 Process
    • 5.4.6.6 End User
    • 5.4.6.7 Stage
    • 5.4.6.8 Deployment
    • 5.4.6.9 Functionality
    • 5.4.6.10 Mode
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 Process
    • 5.4.7.6 End User
    • 5.4.7.7 Stage
    • 5.4.7.8 Deployment
    • 5.4.7.9 Functionality
    • 5.4.7.10 Mode
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 Process
    • 5.5.1.6 End User
    • 5.5.1.7 Stage
    • 5.5.1.8 Deployment
    • 5.5.1.9 Functionality
    • 5.5.1.10 Mode
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 Process
    • 5.5.2.6 End User
    • 5.5.2.7 Stage
    • 5.5.2.8 Deployment
    • 5.5.2.9 Functionality
    • 5.5.2.10 Mode
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 Process
    • 5.5.3.6 End User
    • 5.5.3.7 Stage
    • 5.5.3.8 Deployment
    • 5.5.3.9 Functionality
    • 5.5.3.10 Mode
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 Process
    • 5.5.4.6 End User
    • 5.5.4.7 Stage
    • 5.5.4.8 Deployment
    • 5.5.4.9 Functionality
    • 5.5.4.10 Mode
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 Process
    • 5.5.5.6 End User
    • 5.5.5.7 Stage
    • 5.5.5.8 Deployment
    • 5.5.5.9 Functionality
    • 5.5.5.10 Mode
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 Process
    • 5.5.6.6 End User
    • 5.5.6.7 Stage
    • 5.5.6.8 Deployment
    • 5.5.6.9 Functionality
    • 5.5.6.10 Mode
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 Process
    • 5.6.1.6 End User
    • 5.6.1.7 Stage
    • 5.6.1.8 Deployment
    • 5.6.1.9 Functionality
    • 5.6.1.10 Mode
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 Process
    • 5.6.2.6 End User
    • 5.6.2.7 Stage
    • 5.6.2.8 Deployment
    • 5.6.2.9 Functionality
    • 5.6.2.10 Mode
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 Process
    • 5.6.3.6 End User
    • 5.6.3.7 Stage
    • 5.6.3.8 Deployment
    • 5.6.3.9 Functionality
    • 5.6.3.10 Mode
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 Process
    • 5.6.4.6 End User
    • 5.6.4.7 Stage
    • 5.6.4.8 Deployment
    • 5.6.4.9 Functionality
    • 5.6.4.10 Mode
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 Process
    • 5.6.5.6 End User
    • 5.6.5.7 Stage
    • 5.6.5.8 Deployment
    • 5.6.5.9 Functionality
    • 5.6.5.10 Mode

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 MacroGenics
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 ImmunoGen
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 MorphoSys
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Genmab
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Pieris Pharmaceuticals
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 AbCellera
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Xencor
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Adimab
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 MabSpace Biosciences
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Harbour BioMed
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Zymeworks
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Bicycle Therapeutics
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Crescendo Biologics
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Mabion
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 I-Mab
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us